Initial Remibrutinib (oral, covalent, and highly specific inhibitor of Bruton’s tyrosine kinase (BTK)) data in SS shows good efficacy and safety. Plenary Abs 1113 #ACR22 @RheumNow https://t.co/5Zr0Y1ueAv https://t.co/Iy194YUWNC
Links:
Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a…
http://ow.ly/V3w850Lz2wO
13-11-2022